59% of early-stage melanoma patients responded to immunotherapy before surgery in the NADINA study, reducing adjuvant treatment need.
59% of early-stage melanoma patients responded successfully to immunotherapy before surgery, reducing the need for adjuvant treatment, as per the NADINA study results. Bristol Myers' pre-surgery immunotherapy combo of Opdivo and Yervoy improved skin cancer outcomes in 423 stage 3 melanoma patients, with 83.7% alive without disease worsening after 12 months, versus 57.2% with no neoadjuvant treatment.
June 02, 2024
4 Articles